Southampton, UK: Synairgen plc (LSE: SNG), the respiratory company developing SNG001 (inhaled interferon-beta or IFN-beta) for the treatment of COVID-19
CPhI Predictions for 2022: high manufacturing demand to constrain global ingredients, partnering options and available CDMO capacity. Continued stellar growth
Combatting the pandemic has highlighted the importance of the partnership between biopharma organizations and the contract manufacturing organizations (CMOs) that